Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

BACKGROUND: Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts. PATIENTS AND METHODS: Eligible patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelley, R. K., Verslype, C., Cohn, A. L., Yang, T.-S., Su, W.-C., Burris, H., Braiteh, F., Vogelzang, N., Spira, A., Foster, P., Lee, Y., Van Cutsem, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391701/
https://www.ncbi.nlm.nih.gov/pubmed/28426123
http://dx.doi.org/10.1093/annonc/mdw651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391701/
https://www.ncbi.nlm.nih.gov/pubmed/28426123
http://dx.doi.org/10.1093/annonc/mdw651

Ejemplares similares